Ataxia-Telangiectasia Latest Advances

Clinical, Immunological Findings, and Outcomes of Children with Ataxia-Telangiectasia: A Single Center Experience.

Journal: Pediatric allergy, immunology, and pulmonology

Published: June 17, 2026

UVB Light Activates an S Phase-Dependent DNA Damage Response in Human Keratinocytes Independent of Oxidative Stress.

Journal: Toxicological sciences : an official journal of the Society of Toxicology

Published: June 10, 2026

TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.

Journal: Research square

Published: June 04, 2026

USP1 inhibition promotes RAD18-dependent PCNA degradation and BRCA1 synthetic lethality.

Journal: bioRxiv : the preprint server for biology

Published: May 18, 2026

Integrated Multiomics Analysis Suggests Statin-Associated Perturbation of DNA Repair Signaling in Colorectal Cancer Cells.

Journal: Omics : a journal of integrative biology

Published: May 14, 2026

G2-to-G0 cell cycle exit underlies sensitivity to ATR inhibition via the p53-p21-RB1 axis.

Journal: bioRxiv : the preprint server for biology

Published: May 07, 2026

A potential turn of the tide in ataxia-telangiectasia.

Journal: The Lancet. Neurology

Published: May 01, 2026

ATM Variants and Breast Cancer Risk in North Macedonia: Focus on the Regionally Enriched p.(Leu2492Arg) Variant.

Journal: Balkan medical journal

Published: April 30, 2026

[Retracted] Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer.

Journal: Oncology letters

Published: April 30, 2026

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress Sensitivity.

Journal: bioRxiv : the preprint server for biology

Published: April 27, 2026

A point mutation in the FAT domain constitutively increases the kinase activity of Rad3ATR and bypasses the requirement for 9-1-1 phosphorylation to activate the DNA replication checkpoint.

Journal: PLoS genetics

Published: April 07, 2026

Next-Generation Therapeutic Targets in Triple-Negative Breast Cancer.

Journal: European journal of breast health

Published: March 30, 2026

Ataxia-Telangiectasia Latest Advances

Find the Latest Research About Ataxia-Telangiectasia

Clinical, Immunological Findings, and Outcomes of Children with Ataxia-Telangiectasia: A Single Center Experience.

Clinical, Immunological Findings, and Outcomes of Children with Ataxia-Telangiectasia: A Single Center Experience.

UVB Light Activates an S Phase-Dependent DNA Damage Response in Human Keratinocytes Independent of Oxidative Stress.

UVB Light Activates an S Phase-Dependent DNA Damage Response in Human Keratinocytes Independent of Oxidative Stress.

TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.

TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.

USP1 inhibition promotes RAD18-dependent PCNA degradation and BRCA1 synthetic lethality.

USP1 inhibition promotes RAD18-dependent PCNA degradation and BRCA1 synthetic lethality.

Integrated Multiomics Analysis Suggests Statin-Associated Perturbation of DNA Repair Signaling in Colorectal Cancer Cells.

Integrated Multiomics Analysis Suggests Statin-Associated Perturbation of DNA Repair Signaling in Colorectal Cancer Cells.

G2-to-G0 cell cycle exit underlies sensitivity to ATR inhibition via the p53-p21-RB1 axis.

G2-to-G0 cell cycle exit underlies sensitivity to ATR inhibition via the p53-p21-RB1 axis.

A potential turn of the tide in ataxia-telangiectasia.

A potential turn of the tide in ataxia-telangiectasia.

ATM Variants and Breast Cancer Risk in North Macedonia: Focus on the Regionally Enriched p.(Leu2492Arg) Variant.

ATM Variants and Breast Cancer Risk in North Macedonia: Focus on the Regionally Enriched p.(Leu2492Arg) Variant.

[Retracted] Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer.

[Retracted] Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer.

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress Sensitivity.

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress Sensitivity.

A point mutation in the FAT domain constitutively increases the kinase activity of Rad3ATR and bypasses the requirement for 9-1-1 phosphorylation to activate the DNA replication checkpoint.

A point mutation in the FAT domain constitutively increases the kinase activity of Rad3ATR and bypasses the requirement for 9-1-1 phosphorylation to activate the DNA replication checkpoint.

Next-Generation Therapeutic Targets in Triple-Negative Breast Cancer.

Next-Generation Therapeutic Targets in Triple-Negative Breast Cancer.